Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment
Open Access
- 3 July 2025
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 39 (9) , 2266-2269
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patientsBlood Cancer Journal, 2025
- CREST‐UK: Real‐world effectiveness, safety and outpatient delivery of CPX‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UKBritish Journal of Haematology, 2024
- How I treat refractory and relapsed acute myeloid leukemiaBlood, 2024
- Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian StudyBlood, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemiaLeukemia & Lymphoma, 2021
- Day 14 bone marrow examination in the management of acute myeloid leukemiaAmerican Journal of Hematology, 2017
- Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double‐induction chemotherapy: Analysis from a large, single institution experienceAmerican Journal of Hematology, 2017
- Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosisCancer, 2010
- Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 TrialBlood, 2003